Navigation Links
NIH report on intracranial stent points out need for upcoming large-scale clinical trial
Date:2/14/2008

LOS ANGELES (Feb. 13, 2008) A preliminary study funded by the National Institutes of Health found that a stent designed to open clogged arteries in the brain was successfully deployed in nearly all cases and significantly reduced arterial blockage in the short term. But data on the long-term benefit of the stent, compared to medical treatment alone, were inconclusive, prompting the upcoming launch of a large-scale randomized trial that is expected to provide definitive results.

The NIH Wingspan Registry collected statistics on 129 patients who had an intracranial artery narrowed by at least 70 percent and were experiencing recurrent strokes or transient ischemic attacks (TIAs or mini-strokes) despite being on anti-clotting medication. Treatment included use of the Wingspan intracranial stent developed by Boston Scientific. Seven centers in the United States participated in the trial, and results are published online in the journal Neurology.

Treatment options for stroke patients with severe blockages are extremely limited. As opposed to the situation in blocked heart arteries where options include angioplasty, stenting and surgical bypass, there is no surgical option for these blockages in the brain. This stent may be a major advance for patients with high-grade stenosis (arterial narrowing) who have a stroke or TIA. Previously they could just take medication and expect to have a high recurrent stroke rate, said neurosurgeon Michael J. Alexander, M.D., one of the articles authors and director of the Cedars-Sinai Neurovascular Center. Before coming to Cedars-Sinai Medical Center in 2007, Alexander was founder and director of the Neurovascular Center at Duke University, where he was one of the Wingspan study leaders.

The Wingspan trial followed another NIH-funded study comparing two blood-thinning medications commonly used to treat narrowing of intracranial arteries. The Warfarin-Aspirin Symptomatic Intracranial Disease Study (WASID) f
'/>"/>

Contact: Sandy Van
sandy@prpacific.com
800-880-2397
Cedars-Sinai Medical Center
Source:Eurekalert

Page: 1 2

Related medicine news :

1. US Oncology to Report 2007 Fourth Quarter and Year-End Earnings Results
2. The Quantum Group Reports 4th Quarter and Year End Results for Fiscal Year 2007
3. Kaiser Foundation Health Plan and Hospitals Reports Fourth Quarter and Fiscal Year-End 2007 Financial Results
4. AtriCure Reports Fourth Quarter and Full Year 2007 Record Financial Results
5. Ventas Reports Ten Percent Rise in 2007 Normalized FFO Per Common Share to $2.69
6. AMERIGROUP Reports Q4 Net Income of $31.1 Million or $0.57 Per Diluted Share; Full-Year Net Income of $116.5 Million or $2.16 Per Diluted Share
7. Allscripts Reports Fourth Quarter 2007 Results
8. IRC Reports Claimed Medical Expenses for Auto Injury Claimants Far Outpace Inflation
9. UCI Medical Affiliates, Inc. Reports First Quarter Fiscal Year 2008 Results
10. SearchMedicas Second Quarterly Top Clinical Search Terms Report Reveals Top 25 Oncology, General Medicine and Psychiatry Search Terms Among Medical Professionals
11. The Female Health Company Reports 37% Revenue Growth and Record Profits for First Quarter of FY2008
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/5/2009)NEW ORLEANS, Dec. 5 There have been significant scientific advances in the field of blood cancers, and leading experts continue to gain a better understanding of how certain diseases progress in orde
(Date:12/5/2009)NEW ORLEANS, Dec. 5 Leukemia and myeloproliferative disorders are serious and often deadly blood cancers. Research presented today at the 51st Annual Meeting of the American Society of Hematology int
(Date:12/5/2009)AVIVA today announced the launch of International Solutions, an innovative new international private medical insurance plan which follows the acclaimed modular design of its UK equivalent. In addition
(Date:12/4/2009)NEW YORK, Dec. 4 Care Investment Trust Inc. (NYSE: CRE ) ("Care" or the "Company") today announced that its Board of Directors has declared a dividend of $0.17 per share of common stock. The div
(Date:12/4/2009)WASHINGTON, Dec. 4 The American Association of Homes and Services for the Aging (AAHSA) applauds the Senate for ensuring that the Community Living and Supportive Services (CLASS) provisions remain i
Breaking Medicine News(10 mins):Health News:New Research Demonstrates Advances in Optimizing Treatments and Quality of Life for People With Hard-To-Treat Forms of Blood Cancer 2Health News:New Research Demonstrates Advances in Optimizing Treatments and Quality of Life for People With Hard-To-Treat Forms of Blood Cancer 3Health News:New Research Demonstrates Advances in Optimizing Treatments and Quality of Life for People With Hard-To-Treat Forms of Blood Cancer 4Health News:New Research Demonstrates Advances in Optimizing Treatments and Quality of Life for People With Hard-To-Treat Forms of Blood Cancer 5Health News:New Research Demonstrates Advances in Optimizing Treatments and Quality of Life for People With Hard-To-Treat Forms of Blood Cancer 6Health News:New Research Demonstrates Advances in Optimizing Treatments and Quality of Life for People With Hard-To-Treat Forms of Blood Cancer 7Health News:New Research Demonstrates Advances in Optimizing Treatments and Quality of Life for People With Hard-To-Treat Forms of Blood Cancer 8Health News:Advances in Genetic Understanding and Treatment Protocols Lead to Significant Progress in Leukemia and Myeloproliferative Disorders 2Health News:Advances in Genetic Understanding and Treatment Protocols Lead to Significant Progress in Leukemia and Myeloproliferative Disorders 3Health News:Advances in Genetic Understanding and Treatment Protocols Lead to Significant Progress in Leukemia and Myeloproliferative Disorders 4Health News:Advances in Genetic Understanding and Treatment Protocols Lead to Significant Progress in Leukemia and Myeloproliferative Disorders 5Health News:Advances in Genetic Understanding and Treatment Protocols Lead to Significant Progress in Leukemia and Myeloproliferative Disorders 6Health News:Advances in Genetic Understanding and Treatment Protocols Lead to Significant Progress in Leukemia and Myeloproliferative Disorders 7Health News:Advances in Genetic Understanding and Treatment Protocols Lead to Significant Progress in Leukemia and Myeloproliferative Disorders 8Health News:Advances in Genetic Understanding and Treatment Protocols Lead to Significant Progress in Leukemia and Myeloproliferative Disorders 9Health News:AVIVA's Private Health Insurance Products Solutions Go International 2Health News:Care Investment Trust Inc. Declares Quarterly Dividend of $0.17 Per Share 2
... PHILADELPHIA Researchers from the Abramson Canc...ced today that findings from two large, internatio...r patients with multiple myeloma, a cancer that oc...methasone, patients significantly improved by all ...
...elebrity Fit Club expert/best-selling author Dr. I...tive to Big Easy; Urges residents to give up,pound... Full Gospel Baptist ...and give up the pounds to fight the epidemic of ex...
...EW YORK, Nov. 21 Flagship Global Health,Inc. ("Fl...promotion of,John Flood as its new Chief Executive...f the Board of Flagship. Mr. Flood has been Presid...m will,focus on the strategic direction of the Com...
... new program counters idea that seniors are by nat...) -- Many older adults may mistakenly believe that...ng, but a new pilot program suggests it,s easy to ...to the leaders of a University of California, Los ...
... thalidomide derivative plus dexamethasone improve...ov. 21 (HealthDay News) -- A combination drug regi...nded survival, as well as the time it took for the...dministration regulatory approval in June of 2006 ...
...DMONTON, Alberta, Nov. 21 What would you do if yo...Tommy Beel ate properly,never smoked, wasn,t a dri...p each night. At the young age of 32, he suffered ...com ), Beel shares his,experiences of being strick...
Other Medicine News:Health News:Penn's Abramson Cancer Center part of major phase III study for myeloma 2Health News:Penn's Abramson Cancer Center part of major phase III study for myeloma 3Health News:Challenge Tops 1,040,000 lbs, National Tour Makes 14th Stop in New Orleans for Bayou Classic 2Health News:Challenge Tops 1,040,000 lbs, National Tour Makes 14th Stop in New Orleans for Bayou Classic 3Health News:Challenge Tops 1,040,000 lbs, National Tour Makes 14th Stop in New Orleans for Bayou Classic 4Health News:John H. Flood III Named as CEO of Flagship Global Health, Inc. 2Health News:Aging Isn't About Slowing Down, Experts Say 2Health News:Drug Combo Boosts Multiple Myeloma Survival 2Health News:Drug Combo Boosts Multiple Myeloma Survival 3Health News:The Blessing of a Brain Injury: Author Survives Injury to Brain Following Stroke, Uses Injury as Fuel to Overcome Odds 2
(Date:12/4/2009)DURHAM, N.C., Dec. 4 Oxygen Biotherapeutics, Inc. (OTC Bulletin Board: OXBT) today announced that the first patient has been enrolled in the company,s Phase II-b, dose escalation, clinical trial in S
(Date:12/4/2009)WASHINGTON, Dec. 4 Chemistry World recently highlighted a new report published by the Pharmaceutical Research and Manufacturers of America ( PhRMA ) that identifies 97 new drugs and vaccines in
(Date:12/4/2009)SAN DIEGO, Calif., Dec. 4 Suneva Medical, a privately-held aesthetic medical device company, today announced the appointment of Philip Ranker as Vice President and Chief Financial Officer. In this r
Breaking Medicine Technology:Oxygen Biotherapeutics, Inc. Enrolls First Patient in Traumatic Brain Injury Clinical Trial in Switzerland 2U.S. Pharmaceutical Companies Developing 97 New Drugs and Vaccines to Fight HIV/AIDS 2Suneva Medical Announces Corporate Developments Including Appointment of Philip Ranker as Chief Financial Officer 2Suneva Medical Announces Corporate Developments Including Appointment of Philip Ranker as Chief Financial Officer 3Suneva Medical Announces Corporate Developments Including Appointment of Philip Ranker as Chief Financial Officer 4FDA to Study Ways to Be More Open With Public 47702 1FDA to Study Ways to Be More Open With Public 47702 2FDA to Study Ways to Be More Open With Public 47702 3TV Interferes With Infants Language Development 47700 1TV Interferes With Infants Language Development 47700 2Florida Hospital Cardiovascular Institute Completes House Wide Implementation of the LifeSync 28R 29 Wireless ECG System 47699 1Florida Hospital Cardiovascular Institute Completes House Wide Implementation of the LifeSync 28R 29 Wireless ECG System 47699 2Florida Hospital Cardiovascular Institute Completes House Wide Implementation of the LifeSync 28R 29 Wireless ECG System 47699 3
...dults can improve memory and attention by training...y data presented today at the annual meeting of th...h Zelinski, PhD, lead investigator on the study an...ornia , also reported on new data showing that the... , A total of 487 healthy adults over the age of 6...
...g a steroid drug for multiple sclerosis (MS) in ad...ase activity more than using the MS drug alone, ac...reaking Science Program at the American Academy of... 25 - May 2, 2009. , , For the study, people wi... in monthly "pulses," or three doses over three da...
Other Medicine Technology:Brain Training Improves Memory and Attention and the Effects Last 2Adding Steroid Drug to MS Treatment May Reduce Disease Activity 2
View Mex-3 Portable Xenon Headlight
Light-Tech Model 585T
Light-Tech Model 565
Xenon Surgical Headlight System
Medicine Products: